Tags

Type your tag names separated by a space and hit enter

Early experience with remdesivir in SARS-CoV-2 pneumonia.
Infection. 2020 Oct; 48(5):779-782.I

Abstract

At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.

Authors+Show Affiliations

Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy. emanuele.durante@unicampania.it. Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. emanuele.durante@unicampania.it.Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy. Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

32418190

Citation

Durante-Mangoni, Emanuele, et al. "Early Experience With Remdesivir in SARS-CoV-2 Pneumonia." Infection, vol. 48, no. 5, 2020, pp. 779-782.
Durante-Mangoni E, Andini R, Bertolino L, et al. Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection. 2020;48(5):779-782.
Durante-Mangoni, E., Andini, R., Bertolino, L., Mele, F., Florio, L. L., Murino, P., Corcione, A., & Zampino, R. (2020). Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection, 48(5), 779-782. https://doi.org/10.1007/s15010-020-01448-x
Durante-Mangoni E, et al. Early Experience With Remdesivir in SARS-CoV-2 Pneumonia. Infection. 2020;48(5):779-782. PubMed PMID: 32418190.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early experience with remdesivir in SARS-CoV-2 pneumonia. AU - Durante-Mangoni,Emanuele, AU - Andini,Roberto, AU - Bertolino,Lorenzo, AU - Mele,Ferruccio, AU - Florio,Letizia Lucia, AU - Murino,Patrizia, AU - Corcione,Antonio, AU - Zampino,Rosa, Y1 - 2020/05/16/ PY - 2020/04/04/received PY - 2020/05/12/accepted PY - 2020/5/18/pubmed PY - 2020/10/8/medline PY - 2020/5/18/entrez KW - Antiviral therapy KW - COVID 19 KW - Pneumonia KW - Remdesivir KW - SARS-CoV-2 SP - 779 EP - 782 JF - Infection JO - Infection VL - 48 IS - 5 N2 - At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19. SN - 1439-0973 UR - https://www.unboundmedicine.com/medline/citation/32418190/Early_experience_with_remdesivir_in_SARS_CoV_2_pneumonia_ L2 - https://doi.org/10.1007/s15010-020-01448-x DB - PRIME DP - Unbound Medicine ER -